(Total Views: 618)
Posted On: 05/11/2020 4:26:30 PM
Post# of 153940
TechGuru,
I do read and do agree with many of you statements.
However in this regards, I tend to think severe results are more important and the key to unleash this beast.
According to Dr. Yang's observation, Leronlimab is effective in half to two third of the patients.
It should be easier to demonstrate from 88% death rate in severe patients now the death rate is around 40%.
In non severe, *if* we are effective in half to two third, and the failure rate is not as high as 88%, it will different to demonstrate it
For instance if the only 15% or moderate become severe. And Leronlimab reduce it by half. It will be about 7%. We need more population to proof the change.
Noting that. Not a medical expert. Just running some numbers.
I do read and do agree with many of you statements.
However in this regards, I tend to think severe results are more important and the key to unleash this beast.
According to Dr. Yang's observation, Leronlimab is effective in half to two third of the patients.
It should be easier to demonstrate from 88% death rate in severe patients now the death rate is around 40%.
In non severe, *if* we are effective in half to two third, and the failure rate is not as high as 88%, it will different to demonstrate it
For instance if the only 15% or moderate become severe. And Leronlimab reduce it by half. It will be about 7%. We need more population to proof the change.
Noting that. Not a medical expert. Just running some numbers.
(0)
(0)
